

## **N-terminal residues control proteasomal degradation of RGS2, RGS4, and RGS5 in HEK293 cells**

Johannes Bodenstein, Roger K. Sunahara and Richard R. Neubig

Department of Pharmacology (J.B., R.K.S., R.R.N) and Department of  
Internal Medicine, Cardiovascular Medicine (R.R.N.), The University of  
Michigan Medical School, Ann Arbor, Michigan, 48109

**Running Title:** Proteasomal regulation of RGS expression and function

**Corresponding Author:**

Richard R. Neubig, M.D., Ph.D.

Department of Pharmacology

1301 MSRB III / 1150 W. Medical Center Drive

University of Michigan Medical School

Ann Arbor, MI 48109-0632

(734) 763-3650 (phone) / (734) 763-4450 (fax)

E-mail: RNeubig@umich.edu

**Text pages:** 36

**Tables:** 2

**Figures:** 8

**References:** 40

**Words in Abstract:** 247

**Words in Introduction:** 936

**Words in Discussion:** 1473

**Abbreviations**

[<sup>3</sup>H]InsP<sub>x</sub>, <sup>3</sup>H labeled mono- and polyphosphates of inositol; [<sup>3</sup>H]NMS, *N*-methyl-[<sup>3</sup>H]scopolamine; DMEM, Dulbecco's modified Eagle's medium; fluo-4 AM, glycine,*N*-[4-[6-[(acetyloxy)methoxy]-2,7-difluoro-3-oxo-3*H*-xanthen-9-yl]-2-[2-[2-[bis[2-[(acetyloxy)methoxy]-2-oxoethyl]amino]-5-methylphenoxy]ethoxy]phenyl]-*N*-[2-[(acetyloxy)methoxy]-2-oxoethyl]-, (acetyloxy)methyl ester; GPCR, G protein-coupled receptor; HEPES, *N*-[2-hydroxyethyl]piperazine-*N*-[2-ethanesulphonic acid]; HA, hemagglutinin; HEK, human embryonic kidney; mAChR, muscarinic acetylcholine receptor; MG-132, carbobenzoxy-*L*-leucyl-*L*-leucyl-*L*-leucinal; PCR, polymerase chain reaction; PBS, phosphate-buffered saline; PMSF,

phenylmethanesulfonyl fluoride; RGS, regulator of G protein signaling; SDS, sodium dodecyl sulfate; TCA, trichloroacetic acid; WT, wild-type.

## Abstract

Regulator of G protein signaling (RGS) proteins modulate G protein-coupled receptor (GPCR) signaling. The N-termini of some RGS4-family proteins provide receptor specificity and also contain an N-end rule determinant that results in ubiquitylation and decreased protein expression. The relevance of these mechanisms to other RGS proteins is not fully understood. Thus we examined function, receptor specificity, and expression of R4 subfamily RGS proteins (RGS2, -3, -4, -5, and -8). While the N-terminus plays a key role in protein stability in HEK293 cells, we were unable to demonstrate specificity of RGS2, -3, -4, -5, or -8 for muscarinic receptors ( $M_1$ ,  $M_3$ , and  $M_5$ ). However, cellular RGS activity ( $8 \gg 2$ ) was strongly correlated with expression; RGS4 and 5 had minimal expression and activity. Stabilizing mutations of RGS4 and 5 (C2S) enhanced expression and function with a greater influence on RGS4 than on RGS5. Surprisingly, a predicted destabilizing mutation in RGS8 (A2C) did not markedly affect expression and had no effect on function. In contrast a destabilizing mutation in RGS2 (RGS2-Q2L) recently identified as a rare N-terminal genetic variant in a Japanese hypertensive cohort (Yang et al., *J Hypertens* 23:1497-1505, 2005) showed significantly reduced expression and inhibition of angiotensin II ( $AT_1$ ) receptor-stimulated accumulation of inositol phosphates. Surprisingly, RGS2-Q2R, also predicted to be destabilizing, showed nearly normal expression and function. Thus, proteasomal regulation of RGS expression in HEK293 cells strongly controls RGS function and a novel RGS2 mutation with decreased protein expression could be relevant to the pathophysiology of hypertension in humans.

## Introduction

G protein-coupled receptors (GPCRs) activate heterotrimeric G proteins which mediate a wide array of signaling processes (Foord et al., 2005; Hepler and Gilman, 1992). The amount of G protein activity is governed by a balance between activation and deactivation. The Regulator of G Protein Signaling (RGS) proteins accelerate deactivation and inhibit signaling by acting as GTPase accelerating proteins (GAPs) at active  $G\alpha$  protein subunits (Ross and Wilkie, 2000). They strongly regulate signaling in cellular systems (Anger et al., 2004; Tovey and Willars, 2004) and have important *in vivo* functions such as the regulation of cardiac function (Fu et al., 2006; Zhang et al., 2006), blood pressure (Heximer et al., 2003), neurotransmission (Chen et al., 2004), and vision (Nishiguchi et al., 2004). There are more than 30 RGS domain-containing proteins divided into six subfamilies. Most RGS proteins act on members of the  $G_i$  or  $G_q$  families of G proteins (De Vries et al., 2000; Hollinger and Hepler, 2002; Ross and Wilkie, 2000). Within the RGS4 subfamily (R4) there is substantial promiscuity at  $G\alpha$  subunits *in vitro* (De Vries et al., 2000; Watson et al., 1996) and in cells (Hains et al., 2004) but less is known about the factors that regulate their cellular activity and specificity.

There is emerging evidence that RGS proteins can preferentially inhibit signaling through different GPCRs signaling through the same  $G\alpha$  subunit (Saitoh et al., 2002; Wang et al., 2002; Xu et al., 1999; Zeng et al., 1998). We recently demonstrated that endogenous RGS3 and RGS5 in vascular smooth muscle cells exhibit specificity for the  $M_3$  muscarinic acetylcholine receptor (mAChR) and angiotensin  $AT_{1A}$  receptor, respectively (Wang et al., 2002). One potential mechanism for RGS-GPCR specificity is the formation of signaling complexes through direct binding between the GPCR and RGS proteins (Abramow-Newerly et al., 2006; Benians et al., 2005; Hague et al., 2005). Hepler and colleagues recently demonstrated an interaction between RGS2 and RGS4 and the third intracellular loop (i3) of muscarinic acetylcholine receptors (mAChRs), with tighter binding to the i3 loop of  $M_1$  and  $M_5$  than to that of  $M_3$  mAChRs

(Bernstein et al., 2004). In the present study, we assess the functional significance of this interaction in a cellular context.

Another potential mechanism controlling RGS action is ubiquitin-dependent proteasomal degradation (Varshavsky, 1997). Proteins bearing a degradation signal (N-degron) consisting of a destabilizing N-terminal residue (such as basic or bulky hydrophobic residues) are ubiquitinated on lysine, recognized by the proteasome, and degraded. Some proteins are not intrinsically unstable but are made unstable by N-arginylation through a non-ribosomal arginine transferase (ATE1 gene) that recognizes N-terminal acidic residues such as aspartate, glutamate, or oxidized cysteine (Lee et al., 2005). RGS4, -5 and -16 which have an N-terminal cys<sup>2</sup> (after removal of the initiator methionine) have a relatively short half-life in cells, with expression dramatically increased in the presence of proteasome inhibitors (Davydov and Varshavsky, 2000; Hu et al., 2005; Krumins et al., 2004; Lee et al., 2005). While one would predict reduced function as a consequence of this reduced protein expression, there has not been a direct correlation of expression and function nor have the essential residues been fully defined.

A recent report on polymorphisms in RGS2 in a Japanese hypertensive cohort (Yang et al., 2005) suggests a possible role of proteasome-mediated degradation of mutant RGS2. Blumer and colleagues demonstrated that both homozygous and heterozygous Rgs2 knock-out mice exhibit a strong hypertensive phenotype and prolonged responses to angiotensin II (Heximer et al., 2003) so reduced RGS2 expression could be of considerable pathophysiological significance. Three studies of genetic variations in RGS2 in human hypertension have been reported recently (Riddle et al., 2006; Semplicini et al., 2006; Yang et al., 2005). Only one defined coding sequence mutations (Yang et al., 2005) and two of these mutations, RGS2-Q2L and RGS2-Q2R, are of particular significance since they would be predicted to increase proteasomal degradation by the N-end rule pathway (leu and arg are considered primary destabilizing residues (Varshavsky, 1996)).

Thus in the present study, we investigate the function and expression of members of the R4 subfamily of RGS proteins. Specifically we asked: 1) Do RGS2, -3, -4, -5, and -8 proteins exhibit differential activities and specificity at the  $G\alpha_{q/11}$ -coupled  $M_1$ ,  $M_3$ , and  $M_5$  mAChRs in cells and does the activity of RGS2 correlate with its recently reported *in vitro* binding specificity for the i3 loop of  $M_1$  mAChRs?; 2) To what degree does proteasomal regulation of RGS protein expression account for the differential effects of RGS transfection to inhibit GPCR signaling?; 3) Which amino acids are involved in the N-end rule dependent destabilization of RGS4 and RGS5?; 4) Are the N-terminal RGS2 genetic variants RGS2-Q2L or RGS2-Q2R destabilized by the N-end rule pathway of protein degradation?; and 5) Do RGS2-Q2L or RGS2-Q2R exhibit impaired functional activity to modulate angiotensin II signaling? Surprisingly, the differential binding of RGS2 and RGS4 to  $M_1$  and  $M_5$  versus  $M_3$  mAChRs does not appear to result in receptor selectivity in HEK293T cells. However, low expression of RGS4 and RGS5 does explain their minimal effects on mAChR signaling although this regulation is more pronounced for RGS4 than RGS5 in HEK293T cells. The single cys<sup>2</sup> in the RGS4 and RGS5 sequence is not sufficient for N-end rule mediated destabilization and even the 4 N-terminal residues of RGS4 and RGS5 do not confer substantial proteasome-dependent destabilization of RGS8. Furthermore, in HEK293T cells, only one of the two mutations of gln<sup>2</sup> in RGS2 (RGS2-Q2L but not RGS2-Q2R) results in strong proteasomal degradation and lower expression in HEK293 cells which reduces inhibition of angiotensin II signaling. This alteration may contribute to the pathogenesis of hypertension in these rare patients.

## Materials and Methods

**Materials.** Cell culture media, pcDNA3.1(+) vector and pcDNA3.1(-) vector, Lipofectamine2000, natural mouse laminin, and phosphate-buffered saline (PBS) were from Invitrogen (Carlsbad, CA). High molecular weight poly-D-lysine was from BD Biosciences (Bedford, MA). *Myo*-[<sup>3</sup>H]inositol (82 Ci/mmol) and *N*-methyl-[<sup>3</sup>H]scopolamine ([<sup>3</sup>H]NMS, 84 Ci/mmol) were from Amersham Biosciences (Little Chalfont, Buckinghamshire, UK). Human [<sup>125</sup>I]-Tyr<sup>4</sup>-angiotensin II (2.2 MCi/mmol) was from Perkin Elmer Life Sciences (Boston, MA). Fluo-4 AM and pluronic were from Molecular Probes (Eugene, OR). Hank's basal saline solution was from Cellgro (Herndon, VA). Human angiotensin II acetate was from Sigma-Aldrich (St Louis, MO). MG-132 was from Calbiochem (La Jolla, CA). Antisera were from Santa Cruz Biotechnology (Santa Cruz, CA). SuperSignal West Pico chemiluminescence substrate was from Pierce (Rockford, IL). Other reagents were from Sigma-Aldrich (St Louis, MO), Fisher Scientific (Fair Lawn, NJ), Calbiochem (La Jolla, CA), and Merck (Darmstadt, Germany).

**DNA Constructs.** Mammalian expression vectors encoding the human, full-length, untagged wild-type (WT) angiotensin II type 1 (AT<sub>1</sub>) receptor, M<sub>1</sub> muscarinic acetylcholine receptor (mAChR), M<sub>3</sub> mAChR, M<sub>5</sub> mAChR, or RGS2, -3, -4, -5, or -8 in pcDNA3.1(+) were obtained from the University of Missouri-Rolla cDNA Resource Center ([www.cdna.org](http://www.cdna.org)). Constructs were generated in our laboratory and the primer sequences are available on request. RGS2-Q2L, RGS2-Q2R, and RGS4-C2S were generated by performing QuickChange site-directed mutagenesis (Stratagene, La Jolla, CA). RGS5-C2S, RGS8-A2C, and RGS8-A2C/A3K/L4G were amplified from the polymerase chain reaction (PCR) as KpnI-XhoI fragments in which the primers introduced the mutations. RGS2-WT-HA, RGS2-Q2L-HA, RGS2-Q2R-HA, RGS4-WT-HA, RGS4-C2S-HA, RGS5-WT-HA, RGS5-C2S-HA, RGS8-WT-HA, RGS8-A2C-HA, and RGS8-A2C/A3K/L4G-HA were amplified from the PCR as KpnI-XhoI



fragments in which the antisense primer encoded a C-terminal hemagglutinin (HA)-epitope tag followed by a stop codon. The fragments were isolated and subcloned into pcDNA3.1(+) vector. The open reading frame of all PCR generated constructs was verified by sequencing at the University of Michigan DNA Sequencing Core.

**Cell Culture and Transfections.** Human embryonic kidney (HEK293T) cells were maintained in a humidified incubator at 37°C with 5% CO<sub>2</sub> and grown to 95% confluency in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells were transiently transfected by using Lipofectamine2000 at 4 µl per µg of plasmid DNA and the manufacturer's recommended protocol followed.

For the fluo-4 AM Ca<sup>2+</sup> fluorescence assays, a black 96-well plate (Costar 3916; Corning, NY) was coated with 50 µl laminin/well (80 µg/ml in PBS), incubated for 30 minutes at 37°C, and aspirated. Cells were trypsinized, suspended in DMEM without antibiotics, and seeded at 50,000 cells/well. Cells were transfected 24 hours later with 0 or 10 ng of the appropriate mAChR, and 0 or 100 ng RGS2, -3, -4, -5, or -8 plasmid DNA/well. The total amount of plasmid DNA was adjusted to 110 ng/well with pcDNA3.1(-). After transfection, the cells were incubated for 48 hours prior to performing the fluo-4 AM Ca<sup>2+</sup> fluorescence assays.

For the whole-cell radioligand binding and accumulation of [<sup>3</sup>H]InsP<sub>x</sub> assays, a 24-well plate was coated with 125 µl poly-D-lysine/well (80 µg/ml in water), incubated for 30 minutes at 37°C, and aspirated. The surface area per well of a 24-well plate is approximately 5-fold the surface area per well of a 96-well plate, so the number of cells seeded and plasmid DNA transfected was accordingly scaled up from the protocol for the fluo-4 AM Ca<sup>2+</sup> fluorescence assays. Cells were trypsinized, suspended in DMEM without antibiotics, seeded at 250,000 cells/well, and for the whole-cell accumulation of [<sup>3</sup>H]InsP<sub>x</sub> assays labeled with 1 µCi/ml *myo*-[<sup>3</sup>H]inositol. Cells were transfected 24 hours later with 0 or 50 ng/well of the appropriate mAChR, or 300 ng/well

angiotensin AT<sub>1</sub> receptor, and the appropriate amount of pcDNA3.1(-) or RGS plasmid DNA. The cells were incubated for 48 hours prior to performing the whole-cell radioligand binding and [<sup>3</sup>H]InsP<sub>x</sub> assays.

For Western blotting, a 6-well plate was coated with 500 µl poly-D-lysine/well, incubated for 30 minutes at 37°C, and aspirated. Cells were trypsinized, suspended in DMEM without antibiotics, and seeded at 1.25×10<sup>6</sup> cells/well. Cells were transfected 24 hours later with 2.5 µg of the appropriate RGS plasmid DNA/well. The cells were incubated for 48 hours before pretreatment with MG-132 and preparation of the cell lysates.

**Radioligand binding assays.** Cells were rinsed once with PBS prior to incubation for 3 hours with the appropriate concentration of [<sup>3</sup>H]NMS or for 1 hour with [<sup>125</sup>I]-Tyr<sup>4</sup>-angiotensin II in OptiMEM in saturation binding and competition binding assays. For mAChR binding assays, non-specific binding was defined with 10 µM atropine. The K<sub>D</sub> value of angiotensin II at angiotensin AT<sub>1</sub> receptors (1.1 nM) was measured with saturation binding analysis of specific binding of 10 pM–10 nM [<sup>125</sup>I]-Tyr<sup>4</sup>-angiotensin II and non-specific binding was defined with 1 µM unlabeled angiotensin II. IC<sub>50</sub> values were calculated by displacement of 50 pM [<sup>125</sup>I]-Tyr<sup>4</sup>-angiotensin II by 100 pM–1 µM unlabeled angiotensin II. The binding reaction was stopped by rinsing the cells with PBS once and replacing the labeling medium with ice-cold 5% (w/v) TCA. The plates were left at room temperature for 1 hour to lyse the cells. Cell lysates were transferred to scintillation vials and the radioactivity counted.

**Measurement of Whole-Cell Fluo-4 AM Ca<sup>2+</sup> Fluorescence.** The medium was aspirated and cells loaded with 5 µM fluo-4 AM and 0.01% (v/v) pluronic F-127 (20% solution in DMSO) in a loading buffer consisting of Hank's basal saline solution supplemented with 20 mM HEPES (pH 7.4), 1 mM Ca<sup>2+</sup> (as calcium chloride), 1 mM Mg<sup>2+</sup> (as magnesium chloride), and 2.5 mM probenecid. The cells were incubated for 45 minutes at 37°C, washed twice, and incubated for 30 minutes with loading buffer. A stock concentration of 10 µM carbachol was freshly prepared

in loading buffer for automated injection into the wells by a Wallac Victor 1420 Multilabel Counter (Perkin Elmer Life Sciences, Boston, MA). Fluo-4 AM fluorescence (485 nm excitation, 535 nm emission) was measured 10 times before and 100 times after the carbachol injection (1  $\mu$ M final concentration).

**Measurement of Whole-Cell Accumulation of [ $^3$ H]InsP<sub>x</sub>.** Previously described procedures were followed (Godfrey, 1992). The medium was aspirated and the cells incubated for 1 hour at 37°C with the appropriate concentration of carbachol or 2 hours at 37°C with the appropriate concentration of angiotensin II in DMEM containing 25 mM HEPES (pH 7.4) and 20 mM lithium chloride. The medium was aspirated and replaced with chilled 10 mM formic acid, and the plates left for 1.5 hours at 4°C to lyse the cells. The accumulated [ $^3$ H]InsP<sub>x</sub> was separated by Dowex chromatography, the columns eluted with 1 M ammonium formate and 100 mM formic acid, and the eluates transferred to scintillation vials and the radioactivity counted.

**Preparation of HEK293T Cell Lysates.** HEK293T cells were pretreated for 4 hours with 0 or 20  $\mu$ M MG-132 in DMEM. Cells were rinsed with PBS at room temperature, followed by the addition of 350  $\mu$ l RIPA buffer with protease inhibitors at 4°C. RIPA buffer contained PBS plus 1% (v/v) Igepal CA-630, 0.5% (w/v) sodium deoxycholate, and 0.1% (w/v) sodium dodecyl sulfate (SDS), 0.01% (w/v) phenylmethanesulfonyl fluoride (PMSF), 0.03% (w/v) aprotinin, and 1 mM sodium orthovanadate. Cells were scraped from the well with a 1 ml pipette tip, and the lysate transferred to a microcentrifuge tube. The DNA was sheared by passing the cell lysate 20-times through a 21G-1½" needle, and 2  $\mu$ l of 10 mg/ml PMSF added. The cell lysates were incubated for 1 hour on ice, centrifuged at  $>10,000 \times g$  (14,000 rpm; Eppendorf model 5415) for 20 minutes at 4°C, the supernatants were collected and frozen at -80°C. Protein concentrations were determined with the Bradford method (Bradford, 1976), using bovine serum albumin as standard.

**Western Immunoblots.** Protein samples (6  $\mu$ g lysate/lane) were resolved on a 12% SDS gel, transferred to an Immobilon-P membrane (Millipore, Bedford, MA) and subjected to Western immunoblot analysis. The membrane was blocked with 10 mM Tris (pH 8.0), 150 mM NaCl, and 5% (w/v) non-fat dry milk (blotto) for 15 minutes at room temperature on an orbital shaker. The membrane was probed overnight at 4°C with rabbit anti-actin and rabbit anti-HA primary antibodies diluted 1:300 and 1:800 respectively in the blotto. Thereafter, the membrane was washed with blocking buffer three times, and probed for 2 hours at room temperature with horseradish peroxidase-conjugated goat anti-rabbit secondary antibody diluted 1:8,000 in blotto. After three washes in blocking buffer, the RGS protein bands were visualized on a Kodak Digital Science Image Station (Kodak, New Haven, CT) using the SuperSignal West Pico chemiluminescent substrate, and images quantified with Kodak 1D software.

**Data Analysis.** Data are reported as the mean  $\pm$  S.E. of three to six independent experiments performed in duplicate or triplicate. Prism (version 4.03, GraphPad Software, San Diego, CA) was used to analyze the data. Saturation binding curves were fitted by non-linear least squares regression (one-site binding model) to determine the binding affinity ( $K_D$ ) and maximal number of binding sites ( $B_{max}$ ) of [ $^3H$ ]NMS. One-site competition binding curves were analyzed by non-linear least squares regression with a homologous competition model to estimate both  $K_i$  and  $B_{max}$  values of [ $^{125}I$ ]-Tyr<sup>4</sup>-angiotensin II. Semi-logarithmic dose-response curves were fitted by non-linear least squares regression with a sigmoidal function with unity slope as least squares non-linear fits to determine the  $EC_{50}$  and maximal response ( $E_{max}$ ) obtained with carbachol and the  $IC_{50}$  values of RGS proteins (potency as amount of transfected plasmid DNA per well). Corrected  $IC_{50}$  values were calculated using the Cheng-Prusoff correction by applying the carbachol concentration and  $EC_{50}$  value for carbachol obtained with the appropriate mAChR (see Legend to Table 2). Statistical comparisons were done by using unpaired or paired two-tailed Student's *t* tests, or one-way ANOVA followed by Bonferroni's post-test to determine *P* values. A value of *P* < 0.05 was considered significant.

## Results

**Characterization of Function and Expression of mAChRs in Transiently Transfected HEK293T Cells.** To characterize M<sub>1</sub>, M<sub>3</sub>, and M<sub>5</sub> mAChRs under the conditions of our transient transfections, receptor function was assessed by measuring accumulation of [<sup>3</sup>H]InsP<sub>x</sub> with carbachol and the EC<sub>50</sub> and E<sub>max</sub> values were calculated. Receptor expression levels were assessed from saturation binding of [<sup>3</sup>H]NMS. Data obtained from the functional study and radioligand binding assays are shown in Table 1. M<sub>1</sub> and M<sub>5</sub> mAChRs expressed at equivalent levels, but M<sub>3</sub> mAChRs expressed at a somewhat higher level (2.8-fold, *P* < 0.01). Also, the EC<sub>50</sub> values for carbachol were slightly greater for M<sub>1</sub> versus M<sub>3</sub> (*P* < 0.05; EC<sub>50</sub> ratio = 2.8) and M<sub>1</sub> versus M<sub>5</sub> (*P* < 0.01; EC<sub>50</sub> ratio = 4.9) but the values for M<sub>3</sub> versus M<sub>5</sub> were not different (*P* > 0.05; EC<sub>50</sub> ratio = 1.7). The E<sub>max</sub> values for carbachol among the three mAChRs were not significantly different.

**Differential Functional Activities of RGS Proteins to Inhibit Ca<sup>2+</sup> Signaling.** To assess the activities of different RGS proteins at the same mAChR and specificity of the same RGS at different mAChRs as an initial screen, HEK293T cells were transiently co-transfected with the M<sub>1</sub>, M<sub>3</sub>, or M<sub>5</sub> mAChR and RGS2, -3, -4, -5, or -8. In the absence of RGS proteins, stimulating the three receptors caused a rapid, transient increase in the intracellular Ca<sup>2+</sup> concentration (4-fold over basal). For all three receptors, co-transfection of RGS2, -3, and -8 greatly reduced the Ca<sup>2+</sup> signal when compared to the control traces (Fig. 1). In contrast, RGS4 and RGS5 did not inhibit the Ca<sup>2+</sup> response and cells with RGS4 even showed a small but not statistically significant increase in response. Radioligand binding assays confirmed that co-expression of RGS proteins did not significantly alter the level of [<sup>3</sup>H]NMS binding (data not shown). Quantitation of peak Ca<sup>2+</sup> responses (Fig. 1D) showed that RGS3 and RGS8 inhibited more than RGS2 did at all three receptors. RGS3 and RGS8 reduced signals 60-75% and RGS2 inhibited by 30-50%. For M<sub>1</sub> and M<sub>5</sub> but not M<sub>3</sub> mAChRs, the activities of RGS3 and RGS8

were significantly greater than that of RGS2 ( $P < 0.05$  or  $P < 0.01$ ). Surprisingly, RGS2 inhibited the  $M_3$  mAChR-stimulated  $Ca^{2+}$  signal at least as well as those of  $M_1$  and  $M_5$  mAChRs despite the previously reported stronger binding of RGS2 to the i3 loops of the  $M_1$  and  $M_5$  versus  $M_3$  mAChRs (Bernstein et al., 2004).

**RGS2 and RGS8 Inhibit Accumulation of [ $^3H$ ]InsP<sub>x</sub>** To more quantitatively assess the effects and specificity of RGS2 and RGS8, we investigated the DNA dependence of their effects on accumulation of inositol phosphates (Fig. 2). RGS3 was not included since it has an atypical, long N-terminus with functions not well characterized (Hollinger and Hepler, 2002). Thus we focused on RGS2 and RGS8 which are more structurally related proteins with short N-termini. Whole-cell accumulation of [ $^3H$ ]InsP<sub>x</sub> was measured after stimulating the cells with 200 nM carbachol for 1 hour. As expected, RGS2 and RGS8 inhibited the [ $^3H$ ]InsP<sub>x</sub> response in a DNA dose-dependent fashion (Table 2). Initial examination of the results showed a 4-fold greater IC<sub>50</sub> value for both RGS2 and RGS8 at  $M_5$  versus the  $M_1$  mAChRs (Table 2) however, under the conditions of our transfections there were differences in EC<sub>50</sub> values of carbachol at the three receptors (see Table 1). Thus we applied a Cheng-Prusoff correction (Cheng and Prusoff, 1973) to the RGS inhibition curves. This corrects the RGS plasmid DNA IC<sub>50</sub> values for the differences in carbachol EC<sub>50</sub> values at the three receptors given the 200 nM dose of carbachol used (see Legend to Table 2). After correction of the DNA plasmid IC<sub>50</sub> values for RGS inhibition of receptor function, the potencies of RGS2 at the three receptors were all within a factor of 2, and differences were not statistically significant ( $P > 0.05$ ). RGS8 appeared more active than did RGS2: 8-fold at  $M_1$  mAChRs ( $P < 0.05$ ) but not significantly so at  $M_3$  (2.7-fold) and  $M_5$  mAChRs (1.4-fold). Thus, in contrast to our expectations from Bernstein et al (2004) there was no significant difference in the activity of RGS2 among the three mAChRs and it is certainly no more potent at  $M_1$  than at  $M_3$  receptors.

**Transient Expression Levels of C-terminal HA-tagged RGS Proteins.** One explanation for different effects of RGS transfection (e.g. lack of effect of RGS4 and RGS5) to inhibit

muscarinic responses is differential expression levels of the RGS proteins. To compare expression of RGS2, -4, -5, and -8, a C-terminal HA-epitope tag was incorporated into the expression vector. The C-terminus was chosen since the N-terminus has been implicated in GPCR interactions and regulation of RGS stability (Bernstein et al., 2000; Bernstein et al., 2004; Davydov and Varshavsky, 2000; Zeng et al., 1998). Lysates from HEK293T cells transiently transfected with equal amounts of RGS2, -4, -5, or -8 plasmid DNA were probed with the anti-HA antibody and proteins were detected at the expected molecular weights as shown in Fig. 3A. The lysates were also probed with an actin antibody to confirm equal loading among the lanes. Densitometric analysis of the protein bands (Fig. 3B) showed that the expression levels of RGS4 and RGS5 were equivalent to each other but markedly lower ( $P < 0.001$ ) than those of either RGS2 or RGS8. RGS2 expressed at approximately twice the level of RGS8 though this was not statistically significant ( $P > 0.05$ ). Thus the slightly greater inhibition by RGS8 *versus* RGS2 could not be explained by a lower expression level of RGS2 in HEK293T cells. However, the lower expression levels of RGS4 and RGS5 likely account for their low activity in functional assays. Thus we explored this question further with chemical and genetic manipulations to increase or decrease RGS protein expression.

**Role of N-terminal Sequence and Proteasomal Degradation in Expression of RGS Proteins.** Given the known role of proteasomal degradation of RGS4 and RGS5 (Davydov and Varshavsky, 2000; Krumins et al., 2004; Lee et al., 2005), we explored proteasomal degradation of the other RGS proteins by inhibiting the proteasome with MG-132 as previously described (Krumins et al., 2004). Inhibition of proteasome activity by MG-132 pretreatment (20  $\mu$ M; 4 hours) caused a 3-fold increase in expression of RGS2 (Fig. 4A & B;  $P < 0.001$ ), 20-fold increase for RGS4 (Fig. 4C & D;  $P < 0.001$ ), and 5-fold increase for RGS5 (Fig. 4E & F;  $P < 0.05$ ) and RGS8 (Fig. 4G & H;  $P < 0.001$ ). Thus RGS4 is strongly modulated by proteasomal inhibition while effects on RGS2, -5, and -8 are more modest.

To investigate the identity of N-terminal residues controlling the expression of RGS proteins, mutations of N-end rule determinants were made to attempt to stabilize RGS4 and RGS5 and to destabilize RGS8 (Fig. 5). Expression of RGS4-C2S was 50-fold ( $P < 0.001$ ) greater than wild-type, an effect even larger than that of MG-132 (Fig. 4C & D). Similar increases were seen for RGS4-C2G and RGS4-C2V mutations, as well as for a truncated RGS4 with the first N-terminal 18 amino acids deleted to initiate translation at the next methionine residue (data not shown). MG-132 pretreatment produced no additional increase in expression of the mutant RGS4-C2S ( $P > 0.05$ ) and in the presence of MG-132 expression of the mutant was 3-fold higher than wild-type ( $P < 0.01$ ).

For RGS5, the C2S mutation produced a 5-fold ( $P < 0.05$ ) increase in expression when compared to the wild-type (Fig. 4E & F), which is similar to the increase seen with MG-132 ( $P < 0.05$ ). There was no significant increase in expression of the mutant RGS5-C2S ( $P > 0.05$ ) upon MG-132 pretreatment and expression of the mutant in the presence of MG-132 was not significantly different from wild-type ( $P > 0.05$ ).

To better understand the determinants of the N-end rule for RGS proteins, we attempted to reduce the stability of RGS8 by adding residues from RGS4 (Fig. 5). For RGS8 (Fig. 4G & H), introduction of the single destabilizing cys<sup>2</sup> residue (RGS8-A2C) did not change its expression ( $P > 0.05$ ). Introduction of the first 3 N-terminal residues from RGS4 or RGS5 (RGS8-A2C/A3K/L4G) decreased expression to  $40 \pm 10\%$  of the control value ( $P < 0.01$ ). MG-132 pretreatment caused RGS8-A2C to express at equivalent levels to wild-type ( $P > 0.05$ ) but expression in the presence of MG-132 was still 5-fold lower ( $P < 0.001$ ) for RGS8-A2C/A3K/L4G suggesting effects independent of proteasomal degradation.

Thus of the RGS proteins investigated here in HEK293T cells, RGS4 expression is most strongly regulated by both chemical and genetic manipulations designed to prevent proteasomal degradation, while all RGS proteins show some increase in expression with MG-132. Given the identical N-terminal sequences of RGS4 and RGS5 and literature on instability of RGS5, It is



surprising that there is such a striking difference in our system. Clearly, the identity of the single N-terminal residue at position 2 and even the first 4 residues are not sufficient to govern RGS protein stability. Furthermore, the N-end rule appears to apply only to a selective set of proteins since expression of the RGS8-A2C/A3K/L4G mutant was only increased modestly after pretreatment with MG-132.

**Functional Activities of RGS4, RGS5, and RGS8 N-terminal Mutants.** We assessed the functional implications of higher expression of RGS4-C2S, RGS5-C2S and lower expression of RGS8-A2C/A3K/L4G to dose-dependently inhibit the accumulation of inositol phosphates. HEK293T cells were transiently co-transfected with the M<sub>1</sub> mAChR and increasing amounts of RGS4-WT and RGS4-C2S (Fig. 6A), RGS5-WT and RGS5-C2S (Fig. 6B), and RGS8-WT, RGS8-A2C, and RGS8-A2C/A3K/L4G (Fig. 6C) plasmid DNA. Whole-cell accumulation of [<sup>3</sup>H]InsP<sub>x</sub> was measured after stimulating the cells with 200 nM carbachol for 1 hour. As previously shown for the Ca<sup>2+</sup> signal (Fig. 1D), RGS4-WT and RGS5-WT at 300 ng plasmid DNA/well produced minimal inhibition of the accumulation of [<sup>3</sup>H]InsP<sub>x</sub> (Fig. 6A & B), although the highest plasmid DNA amounts of RGS5 did cause some effect. To prevent overloading the cells with plasmid DNA which may cause significant cell death, even greater amounts were not used. The stable mutants (RGS4-C2S and RGS5-C2S) strongly inhibited the response with a maximal effect of ~75%. While interpretation is complicated somewhat by the small dip in the curves for wild-type RGS4 and RGS5, the apparent leftward shifts in the predicted inhibition curves (50-fold for RGS4-C2S and 10-fold for RGS5-C2S) are largely consistent with the increases in expression observed with these mutants (Fig. 4C, D, E & F).

For RGS8-WT, RGS8-A2C, and RGS8-A2C/A3K/L4G, all three constructs dose-dependently inhibited the response and the curves are practically superimposed (Fig. 6C). While it is somewhat surprising that the mutation RGS8-A2C/A3K/L4G did not decrease RGS8 activity, it should be noted that expression of the mutant is only reduced by 2.5-fold while RGS4-C2S increased 50-fold and RGS5-C2S increased 5-fold compared to the wild-type. A 2.5-fold

reduction in expression might be expected to produce only a modest rightward shift of the dose-response curve, however it is possible that addition of the cys<sup>2</sup> and lys<sup>3</sup> residues enhances membrane localization as well as contributing to protein destabilization. Palmitoylation of N-terminal cysteine residues has been implicated *in vitro* (Tu et al., 1999) and could aid in localizing and orienting the RGS to interact favorably with G $\alpha$  (Jones, 2004), but determining the precise mechanism in this cellular context will require additional study.

**Differential Expression and Stability of RGS2 Genetic Variants.** Given the unpredictability of the second N-terminal residue in mammalian RGS protein degradation, it is unclear whether the RGS2-Q2L and RGS2-Q2R mutations found in the Japanese hypertensive patients would affect RGS2 expression. Interestingly, the RGS2-Q2L mutant was expressed at much lower levels than were the WT or Q2R mutant (Fig. 7A). Also its expression was markedly increased by MG-132. All RGS2 bands were detected at the expected molecular weight (~25 kDa) and equal loading among the lanes was confirmed by actin probing. To ensure that the effect was not due to a second mutation in the plasmid, two separate clones of RGS2-Q2L from the mutagenesis were tested and showed similar decreases in expression (data not shown). Densitometric analysis of the protein bands (Fig. 7B, left panel) shows that RGS2-Q2L expressed at a level 12-fold lower than RGS2-WT ( $P < 0.001$ ) while the expression of RGS2-Q2R was not significantly different from WT. With MG-132 pretreatment (Fig. 7B, right panel), expression of RGS2-WT and RGS2-Q2R were increased 2.5-3-fold which is no different from effects on RGS8 or the stabilized mutants of RGS4 and RGS5. This suggests that neither the RGS2 WT or Q2R mutant is unstable. In contrast, expression of RGS2-Q2L increased 17-fold with MG-132 ( $P = 0.0009$ ), nearly as much as WT RGS4. Thus of the two genetic variants RGS2-Q2L was the most unstable (as confirmed by the lowest expression), and was most strongly regulated by the proteasome (as confirmed by highest fold increase in expression with proteasomal inhibition).

**RGS2-Q2L Function Correlates with Its Reduced Expression.** The functional effects of RGS2 genetic variants to inhibit angiotensin AT<sub>1</sub> receptor-mediated signaling were also assessed. In Fig. 8A, the effect of angiotensin II on accumulation of [<sup>3</sup>H]InsP<sub>x</sub> was measured in HEK293T cells transiently co-transfected with the human angiotensin AT<sub>1</sub> receptor and RGS2-WT, RGS2-Q2L, or RGS2-Q2R. The EC<sub>50</sub> value for angiotensin II to increase the accumulation of [<sup>3</sup>H]InsP<sub>x</sub> was 3 ± 0.6 nM which is consistent with other studies (Modrall et al., 2001). The EC<sub>50</sub> value was not significantly changed (*P* > 0.05) by co-expression of the three RGS2 genetic variants. However, RGS2-WT reduced the angiotensin II E<sub>max</sub> value by 82 ± 6% (Fig. 8, *P* < 0.001). There was no change in the B<sub>max</sub> or K<sub>d</sub> values for [<sup>125</sup>I]-Tyr<sup>4</sup>-angiotensin II binding to receptor transfected alone compared to receptor transfected with RGS2 (data not shown). Therefore as expected the inhibition was distal to the receptor. In contrast RGS2-Q2L decreased the E<sub>max</sub> by only 46 ± 8 % and the magnitude of accumulation of inositol phosphates induced by angiotensin II with RGS2-Q2L transfection was significantly greater than that with WT RGS2 (Fig. 8B, *P* = 0.03). Furthermore, there were no differences in the E<sub>max</sub> values for WT RGS2 and the RGS2-Q2R mutant. Thus of the two gln<sup>2</sup> mutants identified in the hypertensive patients only RGS2-Q2L showed reduced functional activity in inhibiting angiotensin AT<sub>1</sub> receptor-mediated signaling in HEK293 cells, a result consistent with its lower expression.

## Discussion

This study investigated the specificity of several R4 subfamily RGS proteins at the  $G\alpha_{q/11}$ -coupled  $M_1$ ,  $M_3$ , and  $M_5$  mAChRs and determinants of their proteasomal degradation in HEK293T cells. Two major conclusions can be derived from this work: 1) Despite literature evidence for specific interactions of RGS2 and RGS4 with  $M_1$  mAChR 3<sup>rd</sup> intracellular loop, we found little evidence for functional specificity of RGS2, -3, -4, -5 and -8 among mAChRs in HEK293T cells. 2) Differential proteasomal regulation of RGS protein expression plays a major role in the magnitude of their functional activities and we identify a surprising difference between RGS4 and RGS5 in this system. Furthermore, the RGS2-Q2L mutation, identified as a rare non-synonymous polymorphism in a group of Japanese hypertensive patients, dramatically reduced RGS2 protein stability and significantly impaired its modulation of angiotensin signaling.

**RGS-GPCR Specificity in Overexpression Systems.** RGS2, -3, -4, -5, and -8 have been identified to inhibit  $G\alpha_q$ , yet still relatively little is known about determinants of their function. There is substantial published evidence for receptor-dependent specificity of RGS proteins (Saitoh et al., 2002; Wang et al., 2002; Xu et al., 1999; Zeng et al., 1998) and direct binding of RGS2 and -4 to the i3 loop of  $G\alpha_{q/11}$ -coupled mAChRs was recently demonstrated (Bernstein et al., 2004) with greater binding to the  $M_1$  and  $M_5$  i3 loops than for the  $M_3$  i3 loop. However, association with full-length receptors and the functional significance of this interaction in cells was not investigated. In our study, we were unable to find evidence from two functional readouts that RGS2 exhibits any specificity at the full-length  $M_1$ ,  $M_3$ , or  $M_5$  mAChRs. This contrasts with a recent study on  $\alpha_1$ -adrenoceptors (Hague et al., 2005) showing greater binding and functional specificity for the full-length  $\alpha_{1A}$ - over the  $\alpha_{1B}$ -adrenoceptor in transiently transfected HEK293 cells. Hence, direct association between RGS and receptor i3 loops may dictate signaling specificity but perhaps only for some GPCRs in a cellular context.

Our negative results for M<sub>1</sub>/M<sub>3</sub> mAChR selectivity of RGS2 reported here do not invalidate literature on receptor/RGS specificity (Saitoh et al., 2002; Wang et al., 2002; Xu et al., 1999; Zeng et al., 1998), rather they suggest that mechanisms may be more complex than just receptor/RGS binding. Clearly, cell-type specific processes such as scaffold molecules like GAIIP interacting protein (GIPC) may play a role. Indeed, the specificity of endogenous RGS3 for the M<sub>3</sub> mAChR and RGS5 for the angiotensin AT<sub>1A</sub> receptor in rat vascular smooth muscle cells (Wang et al., 2002) that we previously reported could also not be shown by transient overexpression in HEK293T cells. We found that RGS3 inhibited M<sub>3</sub> mAChRs and angiotensin AT<sub>1A</sub> signals equally, while RGS5 inhibited neither (unpublished results, Q. Wang and R. Neubig, University of Michigan). The latter effect is presumably due to the poor expression of RGS5 possibly suggesting that vascular smooth muscle-specific factors may be important for the specificity.

**Role of Proteasome in Control of Signaling Pathways.** A striking observation here and from others (Anger et al., 2004; Tovey and Willars, 2004) was the minimal functional activity that transfection with RGS4 and RGS5 exhibited compared to RGS2 and RGS8. Although it has been demonstrated that the expression of RGS4 (Krumins et al., 2004) and RGS5 (Lee et al., 2005) increased with proteasome inhibitors, surprisingly, there is no published functional data to assess the significance of proteasomal regulation. We provide evidence here that RGS2, -5, and -8 show markedly less regulation in HEK293 cells than does RGS4. Also, the degree of functional activity of the RGS proteins correlates fairly well with their expression levels (Fig. 1-3), but there were some discrepancies. RGS2 showed somewhat less activity than RGS8 despite having about twice the level of expression (as detected by epitope immunoblotting). Furthermore, the mutants RGS4-C2S and RGS5-C2S showed relatively similar functional activity at 100 ng of plasmid while the amount of immunoreactive HA-tagged RGS4 is substantially greater (Fig. 4C & E). Thus while proteasomal regulation plays a major role in

controlling the function of each single RGS protein, there are obviously other determinants of activity when comparing among RGS proteins.

Surprisingly, our results show that RGS5 exhibits markedly less proteasomal regulation than RGS4. Although expression levels of RGS5 in HEK293T cells were low, the increase in its expression with the proteasome inhibitor MG-132 and upon mutation of the  $\text{cys}^2$  to  $\text{ser}^2$  was much less robust than the increases seen with RGS4. This was unexpected, since it was previously shown that both RGS4 and RGS5 were strongly degraded in reticulocyte lysates (Lee et al., 2005). Interestingly in their report, the two splice variants of the ATE1 arginine transferase that lead to destabilization of RGS4 and RGS5 seem to show differential activities (Lee et al., 2005). ATE1-1 strongly suppressed expression of RGS4 and RGS5 in ATE1<sup>-/-</sup> mouse embryonic fibroblasts while the ATE1-2 splice variant seemed to more effectively suppress expression of RGS4 (Lee et al., 2005). Another difference between our study and their report (Lee et al., 2005) concerns their use of a very high MG-132 concentration of 2 mM while we used 20  $\mu\text{M}$  (4 hours pretreatment) which has been reported previously in work on RGS proteins (Krumins et al., 2004). Thus cell-type specific expression of ATE1 splice variants or differential sensitivity to MG-132 may account for the differences between RGS4 and RGS5 in the two studies. Regardless, both RGS4 and RGS5 showed substantial changes in functional activity when proteasomal regulation was reduced by N-terminal mutations. Thus our results clearly support a role for regulation of RGS proteins by proteasomal degradation but they raise new questions about cell-type dependent differences.

It is clear that an N-terminal  $\text{cys}^2$  is needed for the degradation of RGS4 by proteasomal mechanisms (Davydov and Varshavsky, 2000) but it has not been established in cell-based assays if this is sufficient to increase degradation. We demonstrate with the RGS8-A2C mutant that the presence of an N-terminal  $\text{cys}^2$  was not sufficient for making a protein an N-end rule substrate. Furthermore, the mutant RGS8-A2C/A3K/L4G did have reduced expression but there was not significantly enhanced proteasomal degradation based on the modest effect of

MG-132. Thus, elements beyond just the N-terminus likely affect this process. This conclusion is also supported by the different effects of the RGS2-Q2L and Q2R mutations described below. This qualification of the N-end rule is important, given that the mammalian genome encodes ~350 proteins bearing an N-terminal cys<sup>2</sup> (Lee et al., 2005) which clearly is not always intrinsically destabilizing, but can become destabilizing depending on other factors. Compared to the short-lived RGS4 and RGS5, our results with the RGS4-C2S and RGS5-C2S mutants provide the first described gain of function in a classical GPCR-mediated readout. These stabilized analogs will be useful tools to more efficiently study potential therapeutic agents against RGS4 and RGS5 function (Roman et al., 2006; Zhong and Neubig, 2001).

In a Japanese cohort of 1724 hypertensive and 1102 normotensive patients, Yang et al. (2005) identified two rare RGS2 mutations that would be predicted to affect protein stability, RGS2-Q2L and RGS2-Q2R. The former was only seen in hypertensive patients (2 subjects, allele frequency = 0.12% but in no normal subjects) and the latter was seen both in normals (1 subject, allele frequency = 0.09%) and in hypertensive patients (3 subjects, allele frequency = 0.17%). These mutations in RGS2 were of particular interest since the N-terminal residue is implicated in protein stability and even an ~50% decrease in RGS2 expression would be of clear pathophysiological significance given the hypertensive phenotype of both homozygous and heterozygous RGS2 knock-out mice (Heximer et al., 2003). We show that RGS2-Q2L, but surprisingly not the Q2R genetic variant, is unstable in HEK293 cells and its reduced expression results in impaired modulation of AT<sub>1</sub> receptor-mediated signaling. Since both leu<sup>2</sup> and arg<sup>2</sup> are considered primary destabilizing residues (Varshavsky, 1996) we had predicted that the Q2R mutant would also show reduced expression and ability to modulate signaling. Clearly it will be of interest to test expression in vascular smooth muscle cells as well. Such a substantial decrease in expression of RGS2-Q2L, even in heterozygous form, could well be sufficient to contribute to the clinical phenotype.

In conclusion, we were unable to provide functional evidence for RGS2 specificity at M<sub>1</sub> *versus* M<sub>3</sub> mAChRs despite published evidence for interactions with the M<sub>1</sub> receptor i3 loop. However, differential proteasomal regulation of RGS protein expression provides an important mechanism to control RGS activity and hence signaling specificity in cells. Further studies will be needed to fully define the determinants and control of this mechanism for RGS proteins in different cellular contexts but our studies show that this control is quite complex. Furthermore, our results support emerging evidence (Semplicini et al., 2006) that decreased RGS2 protein levels may contribute to the pathogenesis of hypertension. Specifically, we identify the non-synonymous RGS2-Q2L polymorphism as having significant functional effects on RGS2 expression and regulation of angiotensin signaling.



## Acknowledgements

We thank Dr. Qin Wang (University of Michigan) for help with preliminary experiments related to this study and for personal communications about the RGS3 and RGS5 effects on M<sub>3</sub> mAChR and angiotensin AT<sub>1A</sub> receptor function. DNA sequencing was subsidized by the University of Michigan Comprehensive Cancer Center.

## References

- Abramow-Newerly M, Roy AA, Nunn C and Chidiac P (2006) RGS proteins have a signalling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. *Cell Signal* **18**:579-591.
- Anger T, Zhang W and Mende U (2004) Differential contribution of GTPase activation and effector antagonism to the inhibitory effect of RGS proteins on Gq-mediated signaling in vivo. *J Biol Chem* **279**:3906-3915.
- Benians A, Nobles M, Hosny S and Tinker A (2005) Regulators of G-protein signaling form a quaternary complex with the agonist, receptor, and G-protein. A novel explanation for the acceleration of signaling activation kinetics. *J Biol Chem* **280**:13383-13394.
- Bernstein LS, Grillo AA, Loranger SS and Linder ME (2000) RGS4 binds to membranes through an amphipathic alpha -helix. *J Biol Chem* **275**:18520-18526.
- Bernstein LS, Ramineni S, Hague C, Cladman W, Chidiac P, Levey AI and Hepler JR (2004) RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq/11alpha signaling. *J Biol Chem* **279**:21248-21256.
- Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**:248-254.
- Chen H, Clark MA and Lambert NA (2004) Endogenous RGS proteins regulate presynaptic and postsynaptic function: functional expression of RGS-insensitive Galpha subunits in central nervous system neurons. *Methods Enzymol* **389**:190-204.
- Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K<sub>1</sub>) and the concentration of inhibitor which causes 50 per cent inhibition (I<sub>50</sub>) of an enzymatic reaction. *Biochem Pharmacol* **22**:3099-3108.
- Davydov IV and Varshavsky A (2000) RGS4 is arginylated and degraded by the N-end rule pathway in vitro. *J Biol Chem* **275**:22931-22941.

- De Vries L, Zheng B, Fischer T, Elenko E and Farquhar MG (2000) The regulator of G protein signaling family. *Annu Rev Pharmacol Toxicol* **40**:235-271.
- Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, Davenport AP, Spedding M and Harmar AJ (2005) International Union of Pharmacology. XLVI. G protein-coupled receptor list. *Pharmacol Rev* **57**:279-288.
- Fu Y, Huang X, Zhong H, Mortensen RM, D'Alecy LG and Neubig RR (2006) Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects. *Circ Res* **98**:659-666.
- Godfrey P (1992) *Signal Transduction: A Practical Approach*. IRL Press, Oxford.
- Hague C, Bernstein LS, Ramineni S, Chen Z, Minneman KP and Hepler JR (2005) Selective inhibition of alpha1A-adrenergic receptor signaling by RGS2 association with the receptor third intracellular loop. *J Biol Chem* **280**:27289-27295.
- Hains MD, Siderovski DP and Harden TK (2004) Application of RGS box proteins to evaluate G-protein selectivity in receptor-promoted signaling. *Methods Enzymol* **389**:71-88.
- Hepler JR and Gilman AG (1992) G proteins. *Trends Biochem Sci* **17**:383-387.
- Heximer SP, Knutsen RH, Sun X, Kaltenbronn KM, Rhee MH, Peng N, Oliveira-dos-Santos A, Penninger JM, Muslin AJ, Steinberg TH, Wyss JM, Mecham RP and Blumer KJ (2003) Hypertension and prolonged vasoconstrictor signaling in RGS2-deficient mice. *J Clin Invest* **111**:1259.
- Hollinger S and Hepler JR (2002) Cellular regulation of RGS proteins: modulators and integrators of G protein signaling. *Pharmacol Rev* **54**:527-559.
- Hu RG, Sheng J, Qi X, Xu Z, Takahashi TT and Varshavsky A (2005) The N-end rule pathway as a nitric oxide sensor controlling the levels of multiple regulators. *Nature* **437**:981-986.
- Jones TL (2004) Role of palmitoylation in RGS protein function. *Methods Enzymol* **389**:33-55.

- Krumins AM, Barker SA, Huang C, Sunahara RK, Yu K, Wilkie TM, Gold SJ and Mumby SM (2004) Differentially regulated expression of endogenous RGS4 and RGS7. *J Biol Chem* **279**:2593-2599.
- Lee MJ, Tasaki T, Moroi K, An JY, Kimura S, Davydov IV and Kwon YT (2005) RGS4 and RGS5 are in vivo substrates of the N-end rule pathway. *Proc Natl Acad Sci U S A* **102**:15030-15035.
- Modrall JG, Nanamori M, Sadoshima J, Barnhart DC, Stanley JC and Neubig RR (2001) ANG II type 1 receptor downregulation does not require receptor endocytosis or G protein coupling. *Am J Physiol Cell Physiol* **281**:C801-809.
- Nishiguchi KM, Sandberg MA, Kooijman AC, Martemyanov KA, Pott JW, Hagstrom SA, Arshavsky VY, Berson EL and Dryja TP (2004) Defects in RGS9 or its anchor protein R9AP in patients with slow photoreceptor deactivation. *Nature* **427**:75-78.
- Riddle EL, Rana BK, Murthy KK, Rao F, Eskin E, O'Connor DT and Insel PA (2006) Polymorphisms and haplotypes of the regulator of G protein signaling-2 gene in normotensives and hypertensives. *Hypertension* **47**:415-420.
- Roman DL, Talbot JN, Roof RA, Sunahara RK, Traynor JR and Neubig RR (2006) Identification of small molecule inhibitors of Regulator of G-protein Signaling 4 (RGS4) using a high throughput flow cytometry protein interaction assay (FCPIA). *Mol Pharmacol*.
- Ross EM and Wilkie TM (2000) GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. *Annu Rev Biochem* **69**:795-827.
- Saitoh O, Murata Y, Odagiri M, Itoh M, Itoh H, Misaka T and Kubo Y (2002) Alternative splicing of RGS8 gene determines inhibitory function of receptor type-specific Gq signaling. *Proc Natl Acad Sci U S A* **99**:10138-10143.
- Semplicini A, Lenzini L, Sartori M, Papparella I, Calo LA, Pagnin E, Strapazzon G, Benna C, Costa R, Avogaro A, Ceolotto G and Pessina AC (2006) Reduced expression of regulator of

- G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. *J Hypertens* **24**:1115-1124.
- Tovey SC and Willars GB (2004) Single-cell imaging of intracellular Ca<sup>2+</sup> and phospholipase C activity reveals that RGS 2, 3, and 4 differentially regulate signaling via the G<sub>α</sub>q/11-linked muscarinic M3 receptor. *Mol Pharmacol* **66**:1453-1464.
- Tu Y, Popov S, Slaughter C and Ross EM (1999) Palmitoylation of a conserved cysteine in the regulator of G protein signaling (RGS) domain modulates the GTPase-activating activity of RGS4 and RGS10. *J Biol Chem* **274**:38260-38267.
- Varshavsky A (1996) The N-end rule: functions, mysteries, uses. *Proc Natl Acad Sci U S A* **93**:12142-12149.
- Varshavsky A (1997) The ubiquitin system. *Trends Biochem Sci* **22**:383-387.
- Wang Q, Liu M, Mullah B, Siderovski DP and Neubig RR (2002) Receptor-selective effects of endogenous RGS3 and RGS5 to regulate mitogen-activated protein kinase activation in rat vascular smooth muscle cells. *J Biol Chem* **277**:24949-24958.
- Watson N, Linder ME, Druey KM, Kehrl JH and Blumer KJ (1996) RGS family members: GTPase-activating proteins for heterotrimeric G-protein alpha-subunits. *Nature* **383**:172-175.
- Xu X, Zeng W, Popov S, Berman DM, Davignon I, Yu K, Yowe D, Offermanns S, Muallem S and Wilkie TM (1999) RGS proteins determine signaling specificity of Gq-coupled receptors. *J Biol Chem* **274**:3549-3556.
- Yang J, Kamide K, Kokubo Y, Takiuchi S, Tanaka C, Banno M, Miwa Y, Yoshii M, Horio T, Okayama A, Tomoike H, Kawano Y and Miyata T (2005) Genetic variations of regulator of G-protein signaling 2 in hypertensive patients and in the general population. *J Hypertens* **23**:1497-1505.
- Zeng W, Xu X, Popov S, Mukhopadhyay S, Chidiac P, Swistok J, Danho W, Yagaloff KA, Fisher SL, Ross EM, Muallem S and Wilkie TM (1998) The N-terminal domain of RGS4 confers receptor-selective inhibition of G protein signaling. *J Biol Chem* **273**:34687-34690.

Zhang W, Anger T, Su J, Hao J, Xu X, Zhu M, Gach A, Cui L, Liao R and Mende U (2006)

Selective loss of fine tuning of Gq/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy. *J Biol Chem* **281**:5811-5820.

Zhong H and Neubig RR (2001) Regulator of G protein signaling proteins: novel multifunctional drug targets. *J Pharmacol Exp Ther* **297**:837-845.

## Footnotes

This work was supported by National Institutes of Health Research Grant R01 GM39561 (to R. N.).

Reprint requests:

Dr. Richard R. Neubig, M.D., Ph.D.

Department of Pharmacology

1301 MSRB III/Box 0632

1150 W. Medical Center Drive

University of Michigan Medical School

Ann Arbor, MI 48109-0632

E-mail: RNeubig@umich.edu

Present address (J. B.): Department of Pharmacology, School of Pharmacy and Pharmacology,  
University of KwaZulu-Natal, Durban, 4000 South Africa

## Legends for Figures

**Figure 1.** RGS2, -3, and -8 inhibit  $\text{Ca}^{2+}$  signaling by  $\text{G}\alpha_{q/11}$ -coupled  $\text{M}_1$ ,  $\text{M}_3$ , and  $\text{M}_5$  mAChRs. HEK293T cells were loaded with fluo-4 AM and intracellular  $\text{Ca}^{2+}$  changes recorded after addition of 1  $\mu\text{M}$  carbachol. The cells were transiently transfected in 96-well plates with 110 ng/well pcDNA3.1(-) vector, or 10 ng/well  $\text{M}_1$  (A),  $\text{M}_3$  (B), or  $\text{M}_5$  (C) mAChR and with or without 100 ng/well RGS2, -3, -4, -5, or -8 plasmid DNA. The activities of RGS2, -3, and -8 to inhibit the peak mAChR responses are represented in (D). Time course data are the averages of four independent experiments performed in duplicate or triplicate. The error bars in (D) are S.E. Statistical comparisons were by one-way ANOVA followed by Bonferroni's post-test; \*,  $P < 0.05$ ; \*\*,  $P < 0.01$  versus RGS2.

**Figure 2.** Dose-dependent activities of RGS2 and RGS8 DNA to inhibit the accumulation of inositol phosphates. Whole-cell accumulation of  $[^3\text{H}]\text{InsP}_x$  was measured by stimulating the cells with 200 nM carbachol. The cells were transiently transfected in 24-well plates with 50 ng/well of  $\text{M}_1$ ,  $\text{M}_3$ , or  $\text{M}_5$  mAChR DNA and increasing amounts of RGS2 (A) or RGS8 (B) plasmid DNA. The total amount of DNA/well was balanced with pcDNA3.1(-) vector. Dose-response curves are averages of triplicate observations from three independent experiments and were fitted by non-linear least squares analysis. Error bars indicate S.E.



**Figure 3.** RGS4 and RGS5 protein expression is much less than that of RGS2 or RGS8. HEK293T cells were transiently transfected in 6-well plates with 2.5 µg/well of C-terminally HA-tagged RGS2, -4, -5, or -8 plasmid DNA. Cell lysates were analyzed by immunoblotting with antibodies specific for the HA-tag and actin, and RGS protein levels visualized in (A). The blot migration of the molecular weight standards is indicated. Net band intensities were determined as described in Materials and Methods and the RGS protein bands normalized to their corresponding actin bands. The quantified expression of RGS2, -4, and -5 relative to RGS8 is represented in (B). The blot is representative of three different transient transfections with the summary from the three experiments in the bar graph. Error bars indicate S.E. and statistical comparisons of RGS expression *versus* RGS8 were by one-way ANOVA followed by Bonferroni's post-test; \*\*\*,  $P < 0.001$ .

**Figure 4.** The effects of MG-132 and mutations on the expression of RGS2, -4, -5, and -8. Expression of HA-tagged WT or mutant RGS proteins was measured in HEK293T cells as described for Fig. 4. Cells were also treated with or without the proteasome inhibitor MG-132 (20 µM; 4 hours). Expression of each RGS protein relative to the wild-type without MG-132 pretreatment is represented for RGS2 (B), RGS4 (D), RGS5 (F), and RGS8 (H). The blots are representative of three different transient transfections and the error bars in graphs indicate S.E. Statistical comparisons were by Student's two-tailed unpaired t test (B), and one-way ANOVA followed by Bonferroni's post-test (D, F and H): \*,  $P < 0.05$  & \*\*\*,  $P < 0.001$  *versus* WT without MG-132. ††,  $P < 0.01$  and †††,  $P < 0.001$  *versus* WT with MG-132.

**Figure 5.** The N-terminal sequences of wild-type RGS2, -4, -5, -8 and mutants (A) relative to the predictions of the N-end rule for protein stability (B) (Varshavsky, 1996). The gln<sup>2</sup> of RGS2-WT is considered a tertiary destabilizing residue and was mutated to a primary destabilizing leu<sup>2</sup> or arg<sup>2</sup> and RGS2-Q2L or RGS2-Q2R respectively generated. For RGS4-WT and RGS5-WT, the primary destabilizing cys<sup>2</sup> was mutated to a stabilizing ser<sup>2</sup> and RGS4-C2S and RGS5-C2S generated. For RGS8-WT, the stabilizing ala<sup>2</sup> was mutated to a destabilizing cys<sup>2</sup> to generate RGS8-A2C, and the ala<sup>2</sup>-ala<sup>3</sup>-leu<sup>4</sup> sequence was mutated to cys<sup>2</sup>-lys<sup>3</sup>-gly<sup>4</sup> to generate RGS8-A2C/A3K/L4G.

**Figure 6.** Functional effects of RGS4, -5, and -8 mutants. Whole-cell accumulation of [<sup>3</sup>H]InsP<sub>x</sub> was measured by stimulating the cells with 200 nM carbachol. The cells were transiently transfected in 24-well plates with 50 ng/well of M<sub>1</sub> mAChR without RGS or with increasing amounts of RGS plasmid DNA: RGS4-WT or RGS4-C2S (A), RGS5-WT or RGS5-C2S (B), and RGS8-WT, RGS8-A2C or RGS8-A2C/A3K/L4G (C). The total amount of DNA/well was balanced with pcDNA3.1(-) vector. Data are mean ± S.E. of three independent experiments each performed in triplicate. Bold dashed lines indicate the predicted curves at higher amounts of WT RGS4 and RGS5 DNA, and arrows indicate the fold leftward shift obtained with the mutants.

**Figure 7.** Effects of RGS2 genetic variants and proteasomal inhibition on expression. HEK293T cells were transiently transfected in 6-well plates with 2.5 µg/well of C-terminally HA-tagged RGS2-WT, RGS2-Q2L, or RGS2-Q2R plasmid DNA. At 48 h post-transfection, cells were pretreated with the proteasome inhibitor MG-132 (0 or 20 µM; 4 h). Cell lysates were analyzed by immunoblotting with antibodies specific for the HA-tag and actin, and RGS2 protein levels visualized. The migration of the molecular weight standard is indicated (A). Net band intensities were determined as described in “Experimental Procedures” and the RGS protein bands normalized to their corresponding actin bands. The quantified expression of each RGS2 protein relative to WT without MG-132 pretreatment is shown (left panel without MG-132 pretreatment, right panel with MG-132 pretreatment) (B). The blot is representative of three different transient transfections with the summary from the three experiments in duplicate in the bar graph. Error bars indicate S.E. Statistical comparisons were by Student’s two-tailed paired t test; \*\*\*,  $P < 0.001$  versus RGS2-WT without MG-132; †,  $P < 0.05$  and †††,  $P < 0.001$  versus RGS2 construct without MG-132.

**Figure 8.** Effects of RGS2 genetic variants on angiotensin AT<sub>1</sub> receptor-mediated function. HEK293T cells were transiently co-transfected in 24-well plates with 300 ng/well human angiotensin II type 1 (AT<sub>1</sub>) receptor with 50 ng/well pcDNA3.1(-) vector or RGS2-WT, RGS2-Q2L, or RGS2-Q2R plasmid DNA. At 48 h post-transfection, whole-cell accumulation of [<sup>3</sup>H]InsP<sub>x</sub> was measured by stimulating the cells for 2 h with increasing concentrations of human angiotensin II (A). Data are expressed as mean peak [<sup>3</sup>H]InsP<sub>x</sub> levels in counts/min radioactivity for each condition after subtraction of basal levels without angiotensin II (B). Dose-response curves are averages of duplicate observations from three (AT<sub>1</sub> alone and AT<sub>1</sub> + RGS2-WT) to six experiments (AT<sub>1</sub> + RGS2-Q2L or RGS2-Q2R) normalized to the E<sub>max</sub> values obtained with AT<sub>1</sub> alone and were fitted by non-linear least squares analysis. Error bars indicate S.E. and statistical comparison was by Student's two-tailed paired t test; \*, *P* < 0.05 *versus* peak response obtained in the presence of RGS2-WT.

## Tables

**Table 1**

Radioligand binding and functional data for mAChRs.

HEK293T cells were transiently transfected in 24-well plates with 50 ng/well of M<sub>1</sub>, M<sub>3</sub>, or M<sub>5</sub> mAChR plasmid DNA. Whole-cell saturation binding was measured with [<sup>3</sup>H]NMS and the K<sub>D</sub>, B<sub>max</sub> values calculated. Whole-cell accumulation of [<sup>3</sup>H]InsP<sub>x</sub> was measured with increasing concentrations of carbachol and the EC<sub>50</sub> and E<sub>max</sub> values calculated. Results are the mean ± S.E. of three individual experiments performed in duplicate (functional assays) or triplicate (radioligand binding assays). Statistical comparisons were by one-way ANOVA followed by Bonferroni's post-test. <sup>a</sup>, *P* < 0.001 versus M<sub>1</sub> or M<sub>5</sub>; <sup>b</sup>, *P* < 0.001 versus M<sub>1</sub> or M<sub>5</sub>; <sup>c</sup>, *P* < 0.05 or <sup>d</sup>, *P* < 0.01 versus M<sub>1</sub>. The E<sub>max</sub> values (counts per minute radioactivity) obtained for the three receptors were not statistically different (*P* > 0.05).

mAChR	M <sub>1</sub>	M <sub>3</sub>	M <sub>5</sub>
K <sub>D</sub> (nM)	6 ± 0.4	17 ± 1 <sup>a</sup>	6 ± 0.4
B <sub>max</sub> (×10 <sup>6</sup> receptors/cell)	1.3 ± 0.13	3.6 ± 0.14 <sup>b</sup>	1.3 ± 0.16
EC <sub>50</sub> (nM)	593 ± 55	209 ± 71 <sup>c</sup>	114 ± 24 <sup>d</sup>
E <sub>max</sub> (cpm)	3845 ± 162	2734 ± 529	3004 ± 512

**Table 2**

RGS DNA plasmid dose dependency for inhibition of mAChR InsP<sub>x</sub> signals.

HEK293T cells were transiently co-transfected in 24-well plates with 50 ng/well of the M<sub>1</sub>, M<sub>3</sub>, or M<sub>5</sub> mAChR and increasing amounts of RGS2 or RGS8 plasmid DNA. Whole-cell accumulation of [<sup>3</sup>H]InsP<sub>x</sub> was measured with 200 nM carbachol and the IC<sub>50</sub> values calculated. Cheng-Prusoff corrected IC<sub>50</sub> values were calculated from the equation: Corrected IC<sub>50</sub> = IC<sub>50</sub> / (1 + ([carbachol] / EC<sub>50</sub>)). Results are the mean ± S.E. of three individual experiments performed in triplicate.

MACHR	M <sub>1</sub>	M <sub>3</sub>	M <sub>5</sub>
RGS2 DNA			
IC <sub>50</sub> (ng/well plasmid)	56 ± 16	65 ± 19	197 ± 86
Corrected IC <sub>50</sub> (ng/well plasmid)	43 ± 13	43 ± 13	84 ± 37
RGS8 DNA			
IC <sub>50</sub> (ng/well plasmid)	8 ± 2	20 ± 7	38 ± 11
Corrected IC <sub>50</sub> (ng/well plasmid)	7 ± 2	13 ± 5	16 ± 5







Figure 1




**Figure 2**





**Figure 3**



**Figure 4**

# A

RGS constructs	123456789...
RGS2-WT:	MQ[SAMVLAV...
RGS2-Q2L:	ML[ <b>S</b> AMVLAV...
RGS2-Q2R:	MR[ <b>S</b> AMVLAV...
RGS4-WT:	MC[KGLAGLP...
RGS4-C2S:	MS[ <b>S</b> KGLAGLP...
RGS5-WT:	MC[KGLAALP...
RGS5-C2S:	MS[ <b>S</b> KGLAALP...
RGS8-WT:	MA[ <u>AAL</u> ]LMLGC...
RGS8-A2C:	MC[ <b>A</b> AL]LMLGC...
RGS8-A2C/A3K/L4G:	MCKG[ <b>L</b> ]LMLGC...

# B

## N-end rule stability




**Destabilizing residues** 1°: F; L; W; Y; R; K; H; I; T



2°: D; E; C

3°: N; Q


**Stabilizing residues:** G; A; V; S

# Figure 5

**A****B****C****Figure 6**



**Figure 7**



**Figure 8**